Ramky Infra Wins 95-Year Concession for ₹3,000 Cr Pharma Park

Introduction to the Landmark Project

Ramky Infrastructure Limited has announced a significant development in India's industrial infrastructure landscape. The company's wholly-owned subsidiary, Maha Integrated Life Sciences City Limited (MILeS City), has formally signed a concession agreement with the Maharashtra Industrial Development Corporation (MIDC). This agreement paves the way for the development of a state-of-the-art pharmaceutical park in Maharashtra's Raigad district. The project, valued at approximately ₹3,000 crore, is set to be executed on a Public-Private Partnership (PPP) basis and represents a major long-term investment in the region's life sciences sector.

Project Scope and Concession Details

The agreement grants MILeS City a concession period of 95 years, which includes a five-year construction phase followed by a 90-year operational and maintenance term. The project will be developed under a Design, Build, Finance, Operate, and Transfer (DBFOT) model. Spanning a vast area of approximately 1,000 hectares in the Dighi Port Industrial Area, across the Mangaon and Roha taluks, the park is designed to become an integrated hub for pharmaceutical and life sciences companies. The development plan includes dedicated industrial and commercial zones, common amenities, utilities, open spaces, and a comprehensive internal road network to support large-scale industrial operations.

A Strategic Public-Private Partnership

This collaboration between Ramky Infrastructure's subsidiary and MIDC highlights the growing importance of the PPP model in developing critical industrial infrastructure. MILeS City will be responsible for the development, operation, maintenance, and management of the park for the entire concession period. The project aims to create a self-sustaining ecosystem that provides end-to-end infrastructure solutions, from research and development facilities to large-scale manufacturing units. This integrated approach is expected to attract significant domestic and international investment into Maharashtra's pharmaceutical sector.

Key Project Highlights

To provide a clear overview, the core details of the project are summarized below:

Financial Framework and Revenue Streams

The project's financial structure is designed for long-term sustainability. The estimated cost of ₹3,000 crore will cover the entire development phase. Ramky Infrastructure anticipates generating revenue through a diversified model. Key income streams will include land lease premiums and development charges from companies setting up their units within the park. Additionally, the company will earn recurring income from maintenance services and operational charges for providing essential utilities and shared facilities to the businesses operating within the life sciences city.

Market Reaction and Stock Performance

The announcement was received positively by the stock market, reflecting investor confidence in Ramky Infrastructure's growth prospects. On Friday, March 13, 2026, the company's shares on the BSE closed at ₹480.25, marking a notable increase of ₹22.20, or 4.85%. This surge indicates that the market views this long-term project as a significant value addition to the company's portfolio and a catalyst for future revenue growth. The construction component of the project is expected to boost Ramky's order book to approximately ₹13,500 crore.

Boosting Regional Economic Growth

Sunil S Nair, CEO of Ramky Infrastructure Ltd, emphasized the project's broader economic impact. He stated that the development is a milestone for industrial growth and will benefit local communities and businesses. The project is expected to generate substantial direct and indirect employment opportunities, strengthen regional infrastructure, and stimulate growth in ancillary industries. By creating a globally competitive manufacturing environment, the park aims to encourage innovation and attract long-term investment into Maharashtra, solidifying its position as a leading pharmaceutical hub.

Conclusion and Future Outlook

The concession agreement for the Raigad pharmaceutical park marks a pivotal achievement for Ramky Infrastructure, strengthening its position as a leading developer of specialized industrial ecosystems. This 95-year project not only secures a long-term revenue pipeline but also aligns with India's strategic goal of enhancing its pharmaceutical manufacturing capabilities. As the five-year construction phase begins, all eyes will be on the project's execution and its eventual transformation of the region into a premier destination for the life sciences industry.